ATE313527T1 - 4-benzyl-1-(2-(4-hydroxy-phenoxy)-ethyl)- piperidin-3,4-diol - Google Patents

4-benzyl-1-(2-(4-hydroxy-phenoxy)-ethyl)- piperidin-3,4-diol

Info

Publication number
ATE313527T1
ATE313527T1 AT01933833T AT01933833T ATE313527T1 AT E313527 T1 ATE313527 T1 AT E313527T1 AT 01933833 T AT01933833 T AT 01933833T AT 01933833 T AT01933833 T AT 01933833T AT E313527 T1 ATE313527 T1 AT E313527T1
Authority
AT
Austria
Prior art keywords
piperidine
phenoxy
diol
benzyl
hydroxy
Prior art date
Application number
AT01933833T
Other languages
English (en)
Inventor
Alexander Alanine
Bernd Buettelmann
Neidhart Marie-Paule Heitz
Georg Jaeschke
Emmanuel Pinard
Rene Wyler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE313527T1 publication Critical patent/ATE313527T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C07D211/50—Aroyl radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT01933833T 2000-04-25 2001-04-17 4-benzyl-1-(2-(4-hydroxy-phenoxy)-ethyl)- piperidin-3,4-diol ATE313527T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00108769 2000-04-25
PCT/EP2001/004305 WO2001081309A2 (en) 2000-04-25 2001-04-17 4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidine-3,4-diol

Publications (1)

Publication Number Publication Date
ATE313527T1 true ATE313527T1 (de) 2006-01-15

Family

ID=8168543

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01933833T ATE313527T1 (de) 2000-04-25 2001-04-17 4-benzyl-1-(2-(4-hydroxy-phenoxy)-ethyl)- piperidin-3,4-diol

Country Status (18)

Country Link
US (1) US6432985B2 (de)
EP (1) EP1278730B1 (de)
JP (1) JP3831255B2 (de)
KR (1) KR100527527B1 (de)
CN (1) CN1178914C (de)
AR (1) AR028357A1 (de)
AT (1) ATE313527T1 (de)
AU (1) AU785153B2 (de)
BR (1) BR0110233A (de)
CA (1) CA2407345C (de)
DE (1) DE60116080T2 (de)
DK (1) DK1278730T3 (de)
ES (1) ES2254422T3 (de)
MX (1) MXPA02010573A (de)
PE (1) PE20011229A1 (de)
UY (1) UY26681A1 (de)
WO (1) WO2001081309A2 (de)
ZA (1) ZA200208134B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7684859B2 (en) 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
EP1585430B1 (de) 2002-11-14 2017-01-11 Brainsgate Ltd. Chirurgische instrumente und verfahren zur stimulation
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US8010189B2 (en) * 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
WO2007076875A2 (en) * 2006-01-06 2007-07-12 Aarhus Universitet Compounds acting on the serotonin transporter
NZ582124A (en) * 2007-05-21 2012-07-27 Reviva Pharmaceuticals Inc Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents
US8008253B2 (en) 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
WO2009118187A1 (en) * 2008-03-27 2009-10-01 Evotec Neurosciences Gmbh Methods for treating disorders using nmda nr2b-subtype selective antagonist
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
EP2789695B1 (de) 2008-08-12 2019-10-30 Zinfandel Pharmaceuticals, Inc. Anti-Alzheimer-Behandlung von Probanden, die durch Nachweis einer genetischen Variante im TOMM40-Gen bei rs 10524523 identifiziert wurden
GEP201706786B (en) 2011-01-10 2017-12-11 Takeda Pharmaceuticals Co Methods and drug products for treating alzheimer's disease
US8703763B2 (en) * 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
US9675796B2 (en) 2013-11-10 2017-06-13 Brainsgate Ltd. Implant and delivery system for neural stimulator
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
WO2016100940A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator
AR110122A1 (es) * 2016-11-08 2019-02-27 Hoffmann La Roche Fenoxitriazoles

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
TW498067B (en) 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives

Also Published As

Publication number Publication date
ES2254422T3 (es) 2006-06-16
AR028357A1 (es) 2003-05-07
AU6021301A (en) 2001-11-07
CA2407345A1 (en) 2001-11-01
US6432985B2 (en) 2002-08-13
CN1443166A (zh) 2003-09-17
AU785153B2 (en) 2006-10-05
UY26681A1 (es) 2001-10-25
JP3831255B2 (ja) 2006-10-11
DK1278730T3 (da) 2006-05-01
CN1178914C (zh) 2004-12-08
MXPA02010573A (es) 2003-03-10
EP1278730A2 (de) 2003-01-29
ZA200208134B (en) 2004-01-22
US20010047014A1 (en) 2001-11-29
WO2001081309A3 (en) 2002-01-17
PE20011229A1 (es) 2001-12-08
DE60116080T2 (de) 2006-08-24
EP1278730B1 (de) 2005-12-21
WO2001081309A2 (en) 2001-11-01
DE60116080D1 (de) 2006-01-26
JP2004509837A (ja) 2004-04-02
KR20040007216A (ko) 2004-01-24
CA2407345C (en) 2009-04-07
BR0110233A (pt) 2003-01-21
KR100527527B1 (ko) 2005-11-09

Similar Documents

Publication Publication Date Title
ATE313527T1 (de) 4-benzyl-1-(2-(4-hydroxy-phenoxy)-ethyl)- piperidin-3,4-diol
ID29609A (id) Turunan 2-(purin-9-il)-tetrahidrofuran-3,4-diol
NO20041983D0 (no) C-5-modifiserte indazolylprrolotriaziner
BR0104614B1 (pt) charneira.
DE60114153D1 (de) Substituierte arylpyrazine
DE60027561D1 (de) Tintenstrahldrucker
AR028393A1 (es) Iminoazidas substituidas
DE50114415D1 (de) Auswringvorrichtung
DE60140969D1 (de) Bankomat
DE60128634D1 (de) Bankautomat
IT1320120B1 (it) 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-0-tolil-piridin-3-il) -isobutirrammide.
DE60139754D1 (de) Güterücksendeverfahren
IT1320240B1 (it) Macchina curvatrice di profilati.
DK1233101T3 (da) Strygerulle
FI4460U1 (fi) Kalanteri
DE50007064D1 (de) Kalander
DE50102094D1 (de) Kalander
FI20000399A (fi) Kalanteri
DE50105888D1 (de) Kalander
FR2803483B1 (fr) Andaineuse frontale
AR027974A1 (es) 1-aril-ciclopropilmetilamino-1,3,5-triazinas substituidas
DE50101830D1 (de) Kalander
FIU20000395U0 (fi) Kalanteri
FI20000249A (fi) Puhevälitteinen hyperlinkki
FI20021851A0 (fi) Varatun rainan hallinta

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1278730

Country of ref document: EP

REN Ceased due to non-payment of the annual fee